has said that its investigational novel drug candidate, GBR 830 has completed phase 2a studies and will progress to phase 2b studies. The phase 2b studies will start with an enrolment of patients in June 2018.
In the phase 2a studies, GBR 830 showed that greater proportion of patients who received GBR 830 achieved a 50% improvement in disease severity as compared to the placebo. The improvement was found to be much better with GBR 830 treatment on 71 days than on placebo.
In the study, GBR 830 was safe and well-tolerated and most common treatment emergent adverse event was a headache, with no meaningful differences observed between GBR 830 (13%) and placebo-treated (25%) patients.
GBR 830 is a potential drug candidate to reduce inflammation associated with symptoms of atopic dermatitis.